Transplant News and Research RSS Feed - Transplant News and Research

TGH develops unique new method to help high-risk patients receive a lung transplant

TGH develops unique new method to help high-risk patients receive a lung transplant

A unique new method to treat a specific group of patients who are at greater risk of rejecting a donor lung, allowing them to live longer after transplant without rejection, has been developed by the Toronto Lung Transplant Program at Toronto General Hospital, University Health Network. [More]
SCCA's Fred Hutch Bone Marrow Transplant Program achieves higher survival rates

SCCA's Fred Hutch Bone Marrow Transplant Program achieves higher survival rates

The Fred Hutchinson Cancer Research Center Bone Marrow Transplant Program at Seattle Cancer Care Alliance was recently recognized for outperforming its anticipated one-year survival rate for allogeneic transplant patients. [More]
Sanford-Burnham researchers use human pluripotent stem cells to grow new hair

Sanford-Burnham researchers use human pluripotent stem cells to grow new hair

In a new study from Sanford-Burnham Medical Research Institute, researchers have used human pluripotent stem cells to generate new hair. The study represents the first step toward the development of a cell-based treatment for people with hair loss. In the United States alone, more than 40 million men and 21 million women are affected by hair loss. [More]
Monell Center receives NIH grant to develop clinical tool that can predict anosmia

Monell Center receives NIH grant to develop clinical tool that can predict anosmia

Monell Center scientist Kai Zhao, PhD, is principal investigator on a $1.5M 4-year grant from the National Institute on Deafness and Other Communication Disorders, part of the National Institutes of Health, to further develop clinical methodology that can predict the path of air flow through a person's nasal passages. [More]
Cleveland Clinic researcher awarded grant to advance treatment of lethal prostate cancer

Cleveland Clinic researcher awarded grant to advance treatment of lethal prostate cancer

The Prostate Cancer Foundation has presented Nima Sharifi, M.D., Kendrick Family Endowed Chair for Prostate Cancer Research at Cleveland Clinic's Lerner Research Institute, a Challenge Award to advance the treatment of lethal prostate cancer. He is also co-investigator on a second Challenge Award that was also selected for funding. [More]
Astute Medical, bioMérieux sign agreement to develop NephroCheck Test for acute kidney injury

Astute Medical, bioMérieux sign agreement to develop NephroCheck Test for acute kidney injury

bioMérieux, a world leader in the field of in vitro diagnostics, and Astute Medical, Inc., a company dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers, today announced that they have signed a global, semi-exclusive agreement regarding the development of a test for the early risk assessment of acute kidney injury (AKI). [More]
Patients who receive lungs from heavy drinkers more likely to develop severe primary graft dysfunction

Patients who receive lungs from heavy drinkers more likely to develop severe primary graft dysfunction

Lung transplant patients who receive lungs from heavy drinkers are nearly nine times more likely to experience a life-threatening complication called primary graft dysfunction, a Loyola University Medical Center study has found. [More]
Study: Stem cells derived from human female amnion have anti-inflammatory effects

Study: Stem cells derived from human female amnion have anti-inflammatory effects

Stem cells derived from human amnion have for some time been considered promising for cell therapies because of their ease of access, ability to differentiate, and absence of ethical issues. [More]
AbbVie gets European Commission's approval to market VIEKIRAX + EXVIERA for HCV treatment

AbbVie gets European Commission's approval to market VIEKIRAX + EXVIERA for HCV treatment

AbbVie announced that the European Commission has granted marketing authorizations for its all-oral, short-course, interferon-free treatment of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets). The treatment has been approved with or without ribavirin (RBV) for patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver transplant recipients. [More]
New device holds promise for improving the delivery of stem cell therapy for non-healing fractures

New device holds promise for improving the delivery of stem cell therapy for non-healing fractures

A new device that can rapidly concentrate and extract young cells from irrigation fluid used during orthopaedic surgery holds promise for improving the delivery of stem cell therapy in cases of non-healing fractures. UC Davis surgeons plan to launch a "proof-of-concept" clinical trial to test the safety and efficacy of the device in the coming months. [More]
Urinary levels of novel biomarkers linked to adverse long-term outcomes in AKI patients

Urinary levels of novel biomarkers linked to adverse long-term outcomes in AKI patients

High levels of two novel urinary biomarkers early in critical illness are associated with adverse long-term outcomes in patients with acute kidney injury (AKI), according to an international, multi-center study led by University of Pittsburgh School of Medicine Researchers. [More]
Leading cardiac specialists propose new guidelines for donor heart allocation

Leading cardiac specialists propose new guidelines for donor heart allocation

A group of leading cardiac specialists has proposed new guidelines for the allocation of donor hearts to patients awaiting transplant. The changes are aimed at improving the organ distribution process to increase the survival rate of patients awaiting transplant and posttransplant. [More]

Researchers develop novel method to predict risk of liver cancer recurrence after transplantation

UCLA transplantation researchers have developed a novel method that more accurately calculates the risk of disease recurrence in liver cancer patients who have undergone a liver transplant, providing a new tool to help physicians make treatment and surveillance decisions. [More]
DMEK eye surgery at University Hospitals makes a world of difference for Ohio resident

DMEK eye surgery at University Hospitals makes a world of difference for Ohio resident

"I was blind as a bat," said 73-year-old Parma, Ohio, resident John Barsa, who suffered from corneal edema, causing an abnormal accumulation of liquid in the eye leading to swelling of the cornea. [More]
Dallas Cowboys timekeeper ready to get back to work after kidney transplant at UT Southwestern

Dallas Cowboys timekeeper ready to get back to work after kidney transplant at UT Southwestern

Jim Ely tackles life like Mean Joe Greene tackled running backs. A banker, he also worked weekends as a football referee for 38 years and still, at age 83, works as home-game timekeeper for the Dallas Cowboys. [More]
MTF Wound Care division inks group purchasing deal with Premier

MTF Wound Care division inks group purchasing deal with Premier

The Musculoskeletal Transplant Foundation Wound Care division announced today that it has signed a group purchasing agreement with Premier, Inc., a leading healthcare improvement company. The agreement offers Premier alliance members access to MTF Wound Care's innovative line of biologic tissue forms. [More]
Careful blink assessment essential to preserve vision in face transplant procedures

Careful blink assessment essential to preserve vision in face transplant procedures

Face transplantation can dramatically enhance a patient's quality of life after severe facial trauma, but lack of attention to eyelid function and vision can leave patients with impaired vision, corneal exposure, eyelid retraction that occurs when the upper or lower eyelid pulls away from the eyeball, and other eyelid-related complications. [More]
Abbvie’s HOLKIRA PAK for chronic genotype 1 Hepatitis C treatment receives Health Canada approval

Abbvie’s HOLKIRA PAK for chronic genotype 1 Hepatitis C treatment receives Health Canada approval

AbbVie receives Health Canada approval for HOLKIRA PAK (ombitasvir/paritaprevir/ritonavir film-coated tablets; dasabuvir film-coated tablets), an all-oral, short-course (12 weeks for the majority of patients), interferon-free treatment, with or without ribavirin (RBV), for the treatment of patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with cirrhosis. [More]
Medical researchers at Saint Louis University bring hope to those in pain and sickness

Medical researchers at Saint Louis University bring hope to those in pain and sickness

This year, Saint Louis University medical researchers advanced their fields, contributing to human knowledge and bringing hope to those in pain and sickness. [More]
Research: Reducing emergency surgery for common procedures could cut health care costs

Research: Reducing emergency surgery for common procedures could cut health care costs

New research indicates that reducing emergency surgery for three common procedures by 10 percent could cut $1 billion in health care costs over 10 years. [More]